Wednesday October 4, 2000

COMPANY PRESS RELEASE

In Only Three Years, Leading Research Tool Appears in 100 Scientific Publications

More than 400 WAVE® Systems Can Be Found in Top Research Institutions Worldwide

PHILADELPHIA (October 4, 2000) - A study published in the current edition of American Journal of Human Genetics became the 100th scientific publication to reference the research tool, the WAVE® Nucleic Acid Fragment Analysis System. This milestone demonstrates that, since its introduction in 1997, the system is being utilized intensively by leading research institutions worldwide. The WAVE system has become an important tool for genomic research because of its high sensitivity, accuracy, speed and cost-effectiveness.

"Understanding variations or mutations in genes is a critical step in learning more about the cause, onset and progression of various diseases," said Collin D'Silva, chief executive officer, Transgenomic. "For example, with this 100th scientific publication, researchers discovered the cause of a rare but deadly type of pulmonary hypertension, which may eventually lead to early detection and enhanced treatment. With this study and the many others in which the WAVE System has been involved, Transgenomic is excited to play an important role in the discovery of disease causes and treatments."

The 100th Publication

"Familial Primary Pulmonary Hypertension (Gene PHH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor-II Gene" published by a team of scientists led by James A. Knowles, M.D. of the College of Physicians and Surgeons at Columbia University, New York, became the 100th scientific publication to reference the WAVE System when it appeared in volume 67: 737-744, 2000 (October) of the American Journal of Human Genetics (AJHG). Members of the American Society of Human Genetics can access the full article at www.ajhg.org.

The WAVE® System

The WAVE System, also commonly known as DHPLC (denaturing high performance liquid chromatography), analyzes previously identified genes for any variations, changes or mutations. Mutations discovered by DHPLC may provide researchers with critical information about the cause, onset and progression of certain diseases.

Scanning for mutations in genes with the WAVE System relies on the specific binding of complementary strands of the DNA double helix. If a mutation exists, a DNA heteroduplex (pairing of different strands) is formed and the binding is less "tight." High temperatures can be used to denature (melt) the DNA double helix. If a mutation exists, the melting temperature of the heteroduplex will be lower. Partially melted DNA can be easily separated from un-melted DNA homoduplexes (pairings of similar strands) containing no mutation. This method is sensitive, fast, accurate and inexpensive when compared to DNA sequencing.

Transgenomic

Transgenomic, Inc. (San Jose, California and Omaha, Nebraska, USA) is a provider of innovative research tools for the genomics industry, helping to accelerate and improve drug development and diagnostics. Transgenomic has major R&D facilities in San Jose, Calif. and the United Kingdom. Transgenomic's advances in biotechnology offer DNA fragment separation for mutation screening, functional genomics and genotyping for applications in basic research, diagnostics and forensics in laboratories worldwide. Transgenomic has an extensive network of service and applications supporting laboratories throughout the world. The company made its initial public offering of 5,152,000 shares on July 18, 2000 and trades on the NASDAQ under the symbol TBIO and its Web site is at: www.transgenomic.com.

For more information, contact: